Results 221 to 230 of about 1,609,187 (354)

Characterization of the initial C3 convertase of the alternative pathway of human complement. [PDF]

, 1984
Zvi Fishelson, Michael K. Pangburn, Hans J. Müller‐Eberhard   +2 more
openalex   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro. [PDF]

Blood Adv
Ter Avest M, de Boer Z, Langemeijer SMC, van de Kar NCAJ, de Jonge MI, Ter Heine R, Langereis JD.   +6 more
europepmc   +1 more source

Correction: A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. [PDF]

J Biol Chem, 2023
Jensen RK, Pihl R, Gadeberg TAF, Jensen JK, Andersen KR, Thiel S, Laursen NS, Andersen GR.   +7 more
europepmc   +1 more source

Antibody-dependent alternative pathway killing of Haemophilus influenzae type b [PDF]

, 1984
Norman P. Steele, Robert S. Munson, D. M. Granoff, James E. Cummins, R. P. Levine   +4 more
openalex   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Therapeutic targeting of alternative pathway and C5 but not C5a protects from disease development in a preclinical model of autoimmune blistering dermatosis. [PDF]

Front Immunol
Laffer B, Ohms M, Kenno S, Tsui P, Ehlers-Jeske E, Song W, Song WC, Köhl J.   +7 more
europepmc   +1 more source

Interferon-β1a-Induced Thrombotic Microangiopathy: Possible Implication of the Alternative Pathway of the Complement. [PDF]

Kidney Int Rep, 2022
Taghavi M, Stordeur P, Collart F, Dachy B, Pozdzik A, Mesquita MDCF, Nortier J.   +6 more
europepmc   +1 more source

Regulation of the alternative pathway of T cell activation by anti-T3 monoclonal antibody. [PDF]

, 1986
D A Fox, Stuart F. Schlossman, E L Reinherz   +2 more
openalex   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source